NO20082561L - Nye koblede pyrrolderivater - Google Patents

Nye koblede pyrrolderivater

Info

Publication number
NO20082561L
NO20082561L NO20082561A NO20082561A NO20082561L NO 20082561 L NO20082561 L NO 20082561L NO 20082561 A NO20082561 A NO 20082561A NO 20082561 A NO20082561 A NO 20082561A NO 20082561 L NO20082561 L NO 20082561L
Authority
NO
Norway
Prior art keywords
pyrrole derivatives
new coupled
coupled
new
derivatives
Prior art date
Application number
NO20082561A
Other languages
English (en)
Norwegian (no)
Inventor
David William Banner
Hans Hilpert
Bernd Kuhn
Harald Mauser
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37782002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082561(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20082561L publication Critical patent/NO20082561L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20082561A 2005-12-15 2008-06-02 Nye koblede pyrrolderivater NO20082561L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05112210 2005-12-15
PCT/EP2006/069292 WO2007068621A1 (en) 2005-12-15 2006-12-05 Novel fused pyrrole derivatives

Publications (1)

Publication Number Publication Date
NO20082561L true NO20082561L (no) 2008-08-27

Family

ID=37782002

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082561A NO20082561L (no) 2005-12-15 2008-06-02 Nye koblede pyrrolderivater

Country Status (21)

Country Link
US (1) US7696240B2 (ko)
EP (1) EP1966134B1 (ko)
JP (1) JP4955012B2 (ko)
KR (1) KR101355754B1 (ko)
CN (1) CN101351446B (ko)
AR (1) AR058338A1 (ko)
AU (1) AU2006326136B2 (ko)
BR (1) BRPI0619963A2 (ko)
CA (1) CA2637740A1 (ko)
CR (1) CR10027A (ko)
EC (1) ECSP088549A (ko)
HK (1) HK1127058A1 (ko)
IL (1) IL191768A0 (ko)
MA (1) MA30162B1 (ko)
MY (1) MY146491A (ko)
NO (1) NO20082561L (ko)
NZ (1) NZ568594A (ko)
RU (1) RU2434853C2 (ko)
TW (1) TWI363755B (ko)
UA (1) UA95788C2 (ko)
WO (1) WO2007068621A1 (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0418244A (pt) * 2003-12-29 2007-04-17 Sepracor Inc composto, métodos para aumentar a concentração de d-serina e/ou diminuir a concentração de produtos tóxicos da oxidação de d-serina pela daao em um mamìfero, para tratar a esquizofrenia, para tratar ou prevenir a perda de memória e/ou cognição associadas com o mal de alzheimer, para tratar a ataxia ou para prevenir a perda da função neuronal caracterìstica de doenças neurodegenerativas, para intensificar a aprendizagem, memória e/ou cognição e para tratar dor neuropática, e, composição farmacêutica
WO2007006003A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
WO2007047146A2 (en) * 2005-10-11 2007-04-26 Intermune, Inc. Inhibitors of viral replication
WO2007081857A2 (en) 2006-01-06 2007-07-19 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
CN101426372A (zh) * 2006-01-06 2009-05-06 塞普拉柯公司 基于四氢萘酮的单胺再摄取抑制剂
EP2816024B8 (en) 2006-03-31 2018-04-04 Sunovion Pharmaceuticals Inc. Chiral amines
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US20080058395A1 (en) * 2006-06-30 2008-03-06 Sepracor Inc. Fused heterocyclic inhibitors of D-amino acid oxidase
MX2008016525A (es) * 2006-06-30 2009-03-09 Sepracor Inc Inhibidores heterocíclicos fusionados de d-amino ácido oxidasa.
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
CL2007002516A1 (es) * 2006-08-31 2008-05-16 Smithkline Beecham Corp Compuestos derivados de indol indano; composicion farmaceutica; y su uso para tratar hiperglicemia, diabetes tipo 2, tolerancia deteriorada a la glucosa, resistencia a la insulina, sindrome x, dislipidemia.
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
EP2074092A2 (en) * 2007-01-18 2009-07-01 Sepracor Inc. Inhibitors of d-amino acid oxidase
AU2008216382A1 (en) * 2007-02-12 2008-08-21 Array Biopharma, Inc. Novel inhibitors hepatitis C virus replication
ES2705599T3 (es) 2007-04-16 2019-03-26 Abbvie Inc Indoles sustituidos en la posición 7 como inhibidores de mcl-1
RU2470011C2 (ru) 2007-05-31 2012-12-20 Сепракор Инк. Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов
WO2008153129A1 (ja) * 2007-06-14 2008-12-18 Teijin Pharma Limited 尿酸値低下剤
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2010030500A1 (en) * 2008-09-09 2010-03-18 Boehringer Ingelheim International Gmbh Aza-benzimidazolone chymase inhibitors
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
KR20120107947A (ko) 2009-12-25 2012-10-04 다이이찌 산쿄 가부시키가이샤 7원환 화합물 및 그것의 의약 용도
WO2013009582A1 (en) * 2011-07-12 2013-01-17 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
KR101739259B1 (ko) 2015-04-22 2017-05-25 광운대학교 산학협력단 신규 피롤 단량체 및 그 제조방법, 피롤 단량체로부터 합성된 고분자 또는 화합물 및 그 제조방법
WO2017066454A2 (en) 2015-10-14 2017-04-20 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
US20200262794A1 (en) * 2015-12-07 2020-08-20 Wake Forest University Health Sciences Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones
AU2018258338B2 (en) * 2017-04-26 2022-07-14 The Board Of Trustees Of The University Of Illinois Nrf and HIF activators/HDAC inhibitors and therapeutic methods using the same
US11690824B2 (en) 2018-04-10 2023-07-04 The General Hospital Corporation Antibacterial compounds
CN112028815A (zh) * 2019-06-03 2020-12-04 中国药科大学 吲哚类衍生物及其医药用途

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169108A (en) * 1973-08-16 1979-09-25 Sterling Drug Inc. 5(OR 6)-[(Substituted-amino)alkyl]-2,3-naphthalenediols
DK0633886T3 (da) 1992-04-03 2000-12-18 Upjohn Co Farmaceutisk aktive bicyclisk-heterocycliske aminer
GB9225141D0 (en) 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
US6169107B1 (en) * 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
DE4326005A1 (de) 1993-08-03 1995-02-09 Hoechst Ag Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
US5852046A (en) * 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
US5686481A (en) * 1993-12-21 1997-11-11 Smithkline Beecham Corporation Endothelin receptor antagonists
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
MX9700696A (es) 1994-07-27 1997-04-30 Sankyo Co Compuestos heterociclicos, utiles como productores de efecto aloesterico en receptores muscarinicos.
FR2726268B1 (fr) * 1994-10-26 1996-12-06 Adir Nouvelles o-arylmethyl n-(thio)acyl hydroxylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent
JPH10510538A (ja) 1994-12-13 1998-10-13 スミスクライン・ビーチャム・コーポレイション 新規化合物
US5684032A (en) * 1994-12-13 1997-11-04 Smithkline Beecham Corporation Compounds
MY132385A (en) 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
DE19543639A1 (de) 1995-11-23 1997-05-28 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5955492A (en) 1996-03-28 1999-09-21 Smithkline Beecham Corporation Carboxylic acid indole inhibitors of chemokines
DK1014966T3 (da) 1996-05-31 2006-12-04 Allelix Neuroscience Inc Farmaceutisk præparat til behandling af neurologiske og neuropsykiatriske lidelser
FR2754262B1 (fr) 1996-10-08 1998-10-30 Synthelabo Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique
JPH10114654A (ja) 1996-10-09 1998-05-06 Fujisawa Pharmaceut Co Ltd 新規用途
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
GB9716656D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
FR2768146B1 (fr) 1997-09-05 2000-05-05 Oreal Nouveaux composes de la famille des indole-carboxyliques et leur utilisation
CA2317439A1 (en) 1998-01-14 1999-07-22 Wayne J. Brouillette Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
DE69909073T2 (de) 1998-02-12 2004-05-19 De Montfort University Durch hydroxylierung aktivierte wirkstofffreigabe
US6500853B1 (en) * 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
ATE277010T1 (de) 1998-07-08 2004-10-15 Harbor Branch Oceanographic Bis-indolederivate und ihre verwendung als entzündungshemmende mittel
US6589975B2 (en) * 1998-07-08 2003-07-08 The Regents Of The University Of California Synthetic compounds for treatment of inflammation
CA2336909C (en) * 1998-07-15 2009-10-20 Teijin Limited Thiobenzimidazole derivatives which are useful as inhibitors of human chymase activity
US6325991B1 (en) 1998-08-24 2001-12-04 Susan E. Draheim Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase A2
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
GB9902047D0 (en) 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
GB9902459D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
FR2796274B1 (fr) 1999-07-16 2001-09-21 Oreal Utilisation de l'acide 4,6-dimethoxy-indole 2-carboxylique ou de ses derives pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
AU7962200A (en) * 1999-10-29 2001-05-14 Wakunaga Pharmaceutical Co., Ltd Novel indole derivatives and drugs containing the same as the active ingredient
CZ20022353A3 (cs) 2000-01-07 2003-02-12 Universitaire Instelling Antwerpen Deriváty purinu, způsob jejich přípravy a jejich použití
US20030083315A1 (en) * 2000-01-17 2003-05-01 Naoki Tsuchiya Human chymase inhibitors
PT1249450E (pt) * 2000-01-17 2008-01-02 Teijin Pharma Ltd Derivados de benzimidazole como inibidores de quimase humana
DK1325008T3 (da) 2000-07-31 2006-02-13 Hoffmann La Roche Piperazinderivater
EP1341761A1 (en) 2000-10-10 2003-09-10 Smithkline Beecham Corporation SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-$g(g) BINDING AGENTS
DE60223227T8 (de) 2001-02-22 2008-11-27 Teijin Pharma Ltd. Benzo[b]thiophenderivate und Verfahren zu deren Herstellung
CA2444501C (en) 2001-04-11 2009-11-17 Idenix (Cayman) Limited Phenylindoles for the treatment of hiv
TWI317634B (en) * 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
JPWO2004080965A1 (ja) 2003-03-14 2006-06-08 協和醗酵工業株式会社 ニューロペプチドｆｆ受容体拮抗剤
JP2007516203A (ja) 2003-07-09 2007-06-21 バイオリポックス エービー 炎症の治療に有用なインドール類
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US20050089936A1 (en) * 2003-10-23 2005-04-28 Jianping Cai Combinatorial library of 3-aryl-1H-indole-2-carboxylic acid amides
US7396940B2 (en) * 2003-10-23 2008-07-08 Hoffmann-La Roche Inc. Combinatorial library of 3-aryl-1H-indole-2-carboxylic acid
AU2005254782A1 (en) 2004-06-18 2005-12-29 Biolipox Ab Indoles useful in the treatment of inflammation
CA2609980C (en) * 2005-05-27 2015-10-13 Queen's University At Kingston Treatment of protein folding disorders

Also Published As

Publication number Publication date
WO2007068621A1 (en) 2007-06-21
AU2006326136A1 (en) 2007-06-21
US7696240B2 (en) 2010-04-13
NZ568594A (en) 2011-08-26
HK1127058A1 (en) 2009-09-18
JP4955012B2 (ja) 2012-06-20
TWI363755B (en) 2012-05-11
CN101351446A (zh) 2009-01-21
IL191768A0 (en) 2008-12-29
KR101355754B1 (ko) 2014-01-27
MY146491A (en) 2012-08-15
AU2006326136B2 (en) 2012-08-16
ECSP088549A (es) 2008-07-30
AR058338A1 (es) 2008-01-30
MA30162B1 (fr) 2009-01-02
CA2637740A1 (en) 2007-06-21
EP1966134A1 (en) 2008-09-10
US20070142452A1 (en) 2007-06-21
EP1966134B1 (en) 2014-03-12
UA95788C2 (en) 2011-09-12
CR10027A (es) 2008-07-29
JP2009519291A (ja) 2009-05-14
TW200732303A (en) 2007-09-01
RU2008128347A (ru) 2010-01-20
BRPI0619963A2 (pt) 2011-10-25
KR20080070062A (ko) 2008-07-29
RU2434853C2 (ru) 2011-11-27
CN101351446B (zh) 2011-10-05

Similar Documents

Publication Publication Date Title
NO20082561L (no) Nye koblede pyrrolderivater
NO20082388L (no) Heteroaryl substituerte piperidinderivater som L-CPT1 inhibitorer
NO20083514L (no) Heterobicykliske sulfonamidderivater for behandling av diabetes
NO20071593L (no) Pyrimidinderivater
TW200745032A (en) Novel heterobicyclic derivatives
NO20054852L (no) GFAT inhibitorer
NO20076648L (no) Novel thiophene derivatives
NO20075626L (no) Heteroarylbenzamid-derivater for anvendelse som GLK-aktivatorer i behandling av diabetes
WO2007015017A3 (fr) Nouveaux derives de polyquinoleines et leur utilisation therapeutique
NO20091548L (no) Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
TW200626598A (en) Pyrrazolo-pyrimidine derivatives
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
NO20075158L (no) Nye sykliske aminer
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
WO2007048064A3 (en) Amino-pyrimidines as casein kinase ii (ck2) modulators
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
NO20082793L (no) Nye tiofenderivater
NO20093200L (no) Tiazolidinderivater
WO2006005741A3 (en) Piperdine derivatives as renin inhibitors
NO20070445L (no) Pyrimidinderivater.
ATE442349T1 (de) Diacylglycerol-acyltransferase-hemmer
NO20080554L (no) Pyrazolonderivater
NO20070089L (no) DPP-IV inhibitorer
NO20076695L (no) Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application